secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2022-03-14T23:59:59+00:00
Accession:  0001564590-22-010086
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma posts $107.9M cash; FDA path for efzofitimod registrational trial in Q3 2022
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments of $107.9M as of Dec 31, 2021.
- FDA End-of-Phase 2 meeting provides development pathway; registrational trial for efzofitimod in pulmonary sarcoidosis planned to start Q3 2022.
- Orphan drug designation granted for efzofitimod in sarcoidosis.
- ATYR2810 Phase 1 study expected to initiate in H2 2022.
- R&D expenses $23.3M in 2021, expected to increase in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000156459022010086/0001564590-22-010086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000156459022010086/life-8k_20220314.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-010086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer